Publication details
Jaký prospěch přináší denosumab (XGEVA®) pacientům s kostními metastázami solidních nádorů?
| Title in English | WHAT IS THE BENEFIT OF DENOSUMAB (XGEVA®) IN PATIENT WITH SOLID TUMOURS WITH BONE METASTASES? |
|---|---|
| Authors | |
| Year of publication | 2013 |
| Type | Article in Periodical |
| Magazine / Source | Urologické listy |
| MU Faculty or unit | |
| Citation | |
| Field | Other specializations of internal medicine |
| Keywords | prostate cancer; skeletal related events; denosumab; pain; quality of life |
| Description | Prostate cancer, renal cell carcinoma and bladder cancer often metastasize to bone. Untill recently bisphosphonates (BP) were drug of choice in these patients, with various efficacy, indications, mode of administration and toxicity profile. Denosumab is a novel human monoclonal antibody now available for the treatment of cancer induced bone disease with a different mode of action, safety profile and administration. Denosumab was superior in head to head comparisons to zoledronic acid in preventing or delaying first SRE in prostate cancer and breast cancer patients as well as in patients suffering from other solid tumors. Favourable toxicity profile enables administration of denosumab even in patients excluded for bisphosponates use or in patients where dose reductions of BP were necessary. |